Queriendo saber de Allogene en su intento de conseguir CART allógenas que se pudieran utilizar en cualquier persona (Universal), es decir ampliando el actual uso de las CART procedentes del propio paciente, hemos dado con una entrada de David Chang (President and Chief Executive Officer at Allogene Therapeutics) en linkedin hablando de cinco hitos en el primer año de Allogene, tanto en lo empresarial como en lo científico: FIVE FIRST-YEAR MILESTONES BRINGING ALLOGENE CLOSER TO ITS GOAL OF REVOLUTIONIZING CANCER TREATMENT
1) A World-Class Leadership Team
2) One of The Largest Initial Public Offerings in Biotechnology
3) Advancing Allogeneic CAR T (AlloCAR T™) Therapy
"presented an updated analysis of pooled clinical data from two ongoing Phase 1 trials of UCART19, the first allogeneic CAR T-cell therapy in clinical evaluation, in pediatric (the PALL study) and adult (the CALM study) patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL). The analysis suggested that an anti-CD52 mAb may be an important contributor for AlloCAR T™ cell expansion.
"We also presented data from a preclinical study of ALLO-715, our AlloCAR T therapy targeting B-cell maturation antigen (BCMA)"
4) Clearance of Our First Investigational New Drug Application for ALLO-501
"ALLO-501"
5) Establishing In-House, State-of-the-Art Manufacturing
Cuatro empresas (Pfizer, Cellectis, Servier y Allogene) están colaborando para conseguir las CART universales:
Allogene has received from Pfizer the rights to 16 preclinical CAR T assets licensed from Cellectis and Servier and one clinical asset licensed from Servier, UCART19, an allogeneic CAR T therapy that is being developed for treatment of CD19- expressing hematological malignancies.
Cellectis tiene la patente sobre TALENS como método de edición génica.
Sobre Allogene nos ocupamos en otra entrada UCART: no están autorizadas pero están en ello
Le ruego evalúe la presente entrada asignando un valor de 1 a 5, de peor a mejor valorada, usando la opción de comentarios
1) A World-Class Leadership Team
2) One of The Largest Initial Public Offerings in Biotechnology
3) Advancing Allogeneic CAR T (AlloCAR T™) Therapy
"presented an updated analysis of pooled clinical data from two ongoing Phase 1 trials of UCART19, the first allogeneic CAR T-cell therapy in clinical evaluation, in pediatric (the PALL study) and adult (the CALM study) patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL). The analysis suggested that an anti-CD52 mAb may be an important contributor for AlloCAR T™ cell expansion.
"We also presented data from a preclinical study of ALLO-715, our AlloCAR T therapy targeting B-cell maturation antigen (BCMA)"
4) Clearance of Our First Investigational New Drug Application for ALLO-501
"ALLO-501"
5) Establishing In-House, State-of-the-Art Manufacturing
Cuatro empresas (Pfizer, Cellectis, Servier y Allogene) están colaborando para conseguir las CART universales:
Allogene has received from Pfizer the rights to 16 preclinical CAR T assets licensed from Cellectis and Servier and one clinical asset licensed from Servier, UCART19, an allogeneic CAR T therapy that is being developed for treatment of CD19- expressing hematological malignancies.
Cellectis tiene la patente sobre TALENS como método de edición génica.
Sobre Allogene nos ocupamos en otra entrada UCART: no están autorizadas pero están en ello
Le ruego evalúe la presente entrada asignando un valor de 1 a 5, de peor a mejor valorada, usando la opción de comentarios
Comentarios
Publicar un comentario